Avadel Presents New Real-World Data Describing Demographic Characteristics and Comorbidities of Patients with Narcolepsy at ANA 2022
October 24, 2022 16:05 ET
|
Avadel Pharmaceuticals plc
- Results identify mood, sleep and pain disorders as the most common comorbidities in people living with narcolepsy - - Encore presentations at ANA 2022 reinforce positive data from completed Phase...
Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference
September 22, 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
September 07, 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 09, 2022 07:00 ET
|
Avadel Pharmaceuticals plc
Received tentative approval for LUMRYZ™ (sodium oxybate) extended-release for oral suspension from FDA on July 18Advancing key activities to potentially accelerate final approval and shorten launch...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9
August 02, 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Announces Tentative Approval of LUMRYZ™ (sodium oxybate) extended-release oral suspension
July 19, 2022 07:00 ET
|
Avadel Pharmaceuticals plc
- Validates the safety profile and clinical efficacy of LUMRYZ - Pursuing strategies to accelerate final approval DUBLIN, Ireland, July 19, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc...
Avadel Pharmaceuticals Provides Corporate Update
June 29, 2022 16:05 ET
|
Avadel Pharmaceuticals plc
Pursuing strategies to accelerate final approval of FT218 NDAOptimizing cost structure to fund strategic priorities and extend cash runwayContinuing key activities to accelerate launch timing of...
Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on the 2022 Young Investigators Research Forum
June 03, 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, June 03, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 02, 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel to Present Clinical Data for FT218 at SLEEP 2022
May 19, 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, May 19, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the...